Search results
Results from the WOW.Com Content Network
Inflammatory myofibroblastic tumor was initially regarded as a benign tumor that most often developed in the lung and less commonly in almost any organ system or tissue. Over time, however, IMT cases occurred in which the tumor spread into local tissues, metastasized to distal tissues, recurred after treatment, or consisted of neoplastic cells ...
An inflammatory pseudotumor is a cell proliferation and inflammation involving spindle cells, which may occur in many parts of the body, and is of unknown case. [1] According to the WHO classification, three lesional patterns can be observed: Inflammatory myofibroblastic tumour, that can be associated with an ALK gene rearrangement
It is a benign, small tumor located in the skin of the distal areas of the legs and, less commonly, the arm; it has occurred mostly in females. EWSR1-SMAD3-positive fibroblastic tumor was named based on the finding that its tumor cells express a EWSR1-SMAD3 fusion gene. Since its initial description in 2018, a total of 15 cases have been ...
Acral myxoinflammatory fibroblastic sarcoma (AMSF), also termed myxoinflammatory fibroblastic sarcoma (MSF), is a rare, low-grade, soft tissue tumor that the World Health Organization (2020) classified as in the category of rarely metastasizing fibroblastic and myofibroblastic tumors. [1]
Nodular fasciitis occurs in all age groups but most often affects those between 20–40 years old. Males and females are equally affected. NF tumors, which may be tender or painful, typically present as rapidly growing solitary lesions that reach their final size (usually 2–3 cm) within a few weeks. [10]
Direct myofibroblastic differentiation of a progenitor cell resident in a stromal tissue. Homing and recruitment of a circulating mesenchymal precursor which can directly differentiate as above or indirectly differentiate through the other cell types as intermediates. Epithelial to mesenchymal transdifferentiation of an epithelial cell.
Low-grade myofibroblastic sarcoma (LGMS) is a subtype of the malignant sarcomas. [1] As it is currently recognized, LGMS was first described as a rare, atypical myofibroblastic tumor (i.e. a tumor consisting of cells with the microscopic features of fibroblasts and smooth muscle cells) by Mentzel et al. in 1998. [2]
Undifferentiated pleomorphic sarcoma (UPS), also termed pleomorphic myofibrosarcoma, [1] high-grade myofibroblastic sarcoma, and high-grade myofibrosarcoma, [2] is characterized by the World Health Organization (WHO) as a rare, poorly differentiated neoplasm (i.e., an abnormal growth of cells that have an unclear identity and/or cell of origin). [3]